BRAF35 polyclonal antibody, anti-human

Background:
The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.

Research Area: Epigenetics and Nuclear Signaling

Synonyms: HMG20B, BRAF35, HMGX2, HMGXB2, SMARCE1R, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related, SMARCE1-related protein, BRCA2-associated factor 35, HMG

Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration: 1 mg/ml

Storage:
-20°C for 1 year